Ftse Mib
36.471,75
0,12%
DAX
21.732,05
0,01%
S&P 500
6.040,53
-0,50%
NASDAQ
19.627,44
-0,28%
Bitcoin
99.480,56
-1,18%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Lixte Biotechnology Holdings Inc (LIXTW) Lixte Biotechnology Holdings Inc (LIXTW) Notizie

Lixte Biotechnology Holdings Inc

LIXTW
0,028
0,0067 (31,46%)
31 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Warrant Azionario
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
22/1/202523:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/1/202519:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/1/202519:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/1/202519:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202512:18EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/1/202523:23EDGAR2Form 8-K - Current report
27/12/202422:05EDGAR2Form 8-K - Current report
20/12/202422:05EDGAR2Form 8-K - Current report
02/12/202422:05EDGAR2Form 8-K - Current report
12/11/202422:50EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
05/11/202412:21EDGAR2Form S-1/A - General form for registration of securities..
01/11/202422:30EDGAR2Form S-1/A - General form for registration of securities..
29/10/202422:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/10/202422:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/10/202422:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/10/202422:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/10/202419:05EDGAR2Form PRE 14A - Other preliminary proxy statements
23/10/202414:30EDGAR2Form 8-K - Current report
23/10/202412:03EDGAR2Form S-1 - General form for registration of securities under..
05/9/202422:05EDGAR2Form 8-K - Current report
04/9/202414:30GLOBELIXTE Receives U.S. Patent Issue Notification for Immune..
26/8/202414:30GLOBEFirst Patient Dosed with LIXTE’s LB-100 in New Clinical..
19/8/202414:30GLOBELIXTE Biotechnology Provides Update On Recent Activities and..
15/8/202414:30GLOBELIXTE Biotechnology Holdings to Present at Two Investor..
14/6/202420:47EDGAR2Form 8-K - Current report
14/6/202417:00GLOBELIXTE Biotechnology Holdings announces collaboration on a..
14/6/202415:30GLOBELIXTE Biotechnology Holdings to Collaborate with Roche and..
14/6/202414:30EDGAR2Form 8-K - Current report
06/6/202414:30GLOBEScientific Journal Reports Findings that Show LIXTE’s Lead..
05/6/202421:55EDGAR2Form 8-K - Current report
03/6/202414:30GLOBELIXTE Biotechnology Holdings Names Distinguished Oncologist..
29/5/202423:29EDGAR2Form 8-K - Current report
20/5/202423:05EDGAR2Form 8-K - Current report
09/5/202418:00EDGAR2Form 8-K - Current report
09/5/202414:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202415:25GLOBELIXTE Biotechnology Co-Sponsoring International Scientific..
24/4/202421:25APSMixed Shelf Filing Gives Micro Cap Delayed Boost
27/3/202420:35APSBiotech Steals The Show Following Pre-Clinical Data..
27/3/202413:30GLOBENEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD..
21/3/202413:30GLOBELIXTE Provides Update on Progress with LB-100 as a PP2A..
27/2/202414:30GLOBEProfessor René Bernards to Present New Pre-Clinical Data on..
26/2/202414:30GLOBELIXTE Biotechnology Enters into Exclusive Immune Oncology..
Apertura: 0,028 Min: 0,028 Max: 0,028
Chiusura: 0,0213

La tua Cronologia

NASDAQ
LIXTW
Lixte Biotechnology
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci